Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
128 hedge funds and large institutions have $335M invested in Progenics Pharmaceuticals Inc in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
2% less capital invested
Capital invested by funds: $343M → $335M (-$8.12M)
5% less funds holding
Funds holding: 135 → 128 (-7)
27% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $1.38M
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$7.81M |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$5.59M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$4.76M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.86M |
| 5 |
BlackRock
New York
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.1M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$8.98M |
| 3 |
PA
Pinnacle Associates
New York
|
-$6.43M |
| 4 |
PFC
Phocas Financial Corp
Alameda,
California
|
-$5.17M |
| 5 |
RA
Royce & Associates
New York
|
-$4.93M |
PGNX Hedge Fund Activity: Q4 2019 in Review
128 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2019, worth a combined $335M — down 2.4% from $343M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of PGNX and 18 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 44 added.
The largest buyer was Broadfin Capital, adding an estimated $7.81M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.1M sold.
- 128 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2019, down from 135 in Q3 2019.
- Funds reported $335M of Progenics Pharmaceuticals Inc stock for Q4 2019, down 2.4% quarter-over-quarter.
- 18 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2019 and 25 closed out, a net change of -7 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q4 2019 was Broadfin Capital, an estimated $7.81M added.
- The largest Progenics Pharmaceuticals Inc seller in Q4 2019 was Point72 Asset Management, an estimated $14.1M sold.
Based on aggregated 13F filings for Q4 2019.